RoslinCT

RoslinCT

Biotechnology Research

Your Advanced Cell & Gene Therapy CDMO Partner

About us

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com.

Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Edinburgh
Type
Privately Held
Founded
2016
Specialties
Gap Analysis, Tissue Procurement, Process Development, Optimisation & Scale-Up, GMP Manufacture, Cell Banking, In-Process and Final Product QC Testing, QP Batch Certification, GMP Storage, and Controlled Temperature Distribution to Clinical Sites Worldwide

Locations

Employees at RoslinCT

Updates

Similar pages

Browse jobs

Funding

RoslinCT 2 total rounds

Last Round

Private equity

Investors

GHO Capital
See more info on crunchbase